Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Brain Cancer treatment details. Immunotherapy. Radiation. University of California San Francisco, San Francisco, CA, United States

Survival: 14.9 months
Toxicity Grade: 4
Treatments: Immunotherapy
Country: United States
City/State/Province: San Francisco, CA
Hospital: University of California San Francisco
Journal: Link
Date: 1/2009

Patients: This phase 2 study involved 30 patients with newly diagnosed glioblastoma. There were 14 men and 16 women. The median age was 53, ranging from 26 to 76 years.

Treatment: Patients were treated with radiation therapy and the immune therapy poly-ICLC (polyinosinic-polycytidylic acid, made stable by adding polylysine and carboxymethylcellulose). Polyinosinic-polycytidylic acid is a small molecule that activates certain cells of the immune system

Toxicity: One grade 4 toxicity, fatigue, was reported. Grade 3 toxicities were reported in less than five patients each and were fatigue, leucopenia, lymphocytopenia, myalgia, fever, thrombosis, pain, and chills.

Results: The median overall survival time was 14.9 months (65 weeks).

Support: This study was supported by Oncovir Inc., which developed the immune therapy used in this research study.

Correspondence: Dr. Nicholas Butowski

E-mail to a Friend Email Physician More Information